Brien M. Bergner

Attorney Docket No.: 082368-001500US Client Reference No.: E1-A0305Y1P-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ITO and SAITO

Application No.: 10/518,472

Filed: October 4, 2005

For: PRIMARY CULTURED

ADIPOCYTES FOR GENE THERAPY

Confirmation No.: 8056

Examiner: Sajjadi, Fereydoun Ghotb

Art Unit: 1633

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER

37 CFR §1.97 and §1.98

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

References DQ and DT cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. These references were originally cited on a Supplemental Information Disclosure Statement submitted March 30, 2007, but contained minor typographical errors. Applicant submits the attached to correct said errors.

Copies of the references are not enclosed, as they were presented with the original submission of March 30, 2007.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

ITO and SAITO PATENT

Application No.: 10/518,472

Page 2

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the

information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses

all the possible relevant information.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct

any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

/Kevin Bastian/

Kevin Bastian Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP

Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300

KLB:bmb 61058847 v1

Substitute for form 1449A&B/PTO				Complete if Known		
				Application Number	10/518,472	
INFORMATION DISCLOSURE				Filing Date	October 4, 2005	
STATEMENT BY APPLICANT			ANT	First Named Inventor	Ito, Masashi	
				Art Unit	1633	
(Use as many sheets as necessary)				Examiner Name	Sajjadi, Fereydoun Ghotb	
Sheet	1	of	1	Attorney Docket Number	082368-001500US	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	No. ¹	Fo Country Code ³	oreign Patent Do	cument Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T^6
	DQ	WO	01/11011	A2	02-15-2001	FURCHT, Leo T., et al.		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	DT	SIMONSON, Gregg D., et al.; "Synthesis and Processing of Genetically Modified Human Proinsulin by Rat Myoblast Primary Cultures;" <u>Human Gene Therapy;</u> January 1, 1996; pp. 71-78; 7:1.				

Signature Considered	Examiner Signature		Date Considered	
----------------------	-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.